Published in Proc Natl Acad Sci U S A on September 01, 1987
Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27
Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med (1994) 1.66
Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest (1993) 1.62
Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest (1988) 1.53
Transcriptional control of the TNF gene. Curr Dir Autoimmun (2010) 1.32
Constitutive activity of the tumor necrosis factor promoter is canceled by the 3' untranslated region in nonmacrophage cell lines; a trans-dominant factor overcomes this suppressive effect. Proc Natl Acad Sci U S A (1992) 1.31
Suppression of tumor-forming ability and related traits in MCF-7 human breast cancer cells by fusion with immortal mammary epithelial cells. Proc Natl Acad Sci U S A (1990) 1.24
Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci U S A (1988) 1.23
Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule. Proc Natl Acad Sci U S A (1991) 1.17
Tumour necrosis factor. Br Med J (Clin Res Ed) (1988) 1.12
Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed) (2011) 1.12
Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin. Am J Pathol (1997) 1.12
Tumor cell surface alpha 4 beta 1 integrin mediates adhesion to vascular endothelium: demonstration of an interaction with the N-terminal domains of INCAM-110/VCAM-1. Cell Regul (1991) 1.10
Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. Proc Natl Acad Sci U S A (1989) 1.09
Tumour necrosis factor: a cytokine with multiple biological activities. Br J Cancer (1990) 1.04
Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example. Int J Mol Sci (2010) 0.91
Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. Br J Cancer (1991) 0.90
Epithelial ovarian cancer: a cytokine propelled disease? Br J Cancer (1991) 0.89
Cytokine profile of Ehrlich ascites tumor treated with Bothrops jararaca venom. Mediators Inflamm (2002) 0.85
Sensitivity to tumour necrosis factor-mediated cytolysis is unrelated to manganous superoxide dismutase messenger RNA levels among transformed mouse fibroblasts. Immunology (1991) 0.84
Cross-talk between receptor tyrosine kinase and tumor necrosis factor-α signaling networks regulates apoptosis but not proliferation. Mol Cell Proteomics (2012) 0.81
Effects of botulinum toxin type D on secretion of tumor necrosis factor from human monocytes. Mol Cell Biol (1989) 0.79
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry (1979) 180.95
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature (1986) 11.09
Tumor necrosis factor (TNF). Science (1985) 8.80
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med (1986) 6.32
Molecular cloning of the complementary DNA for human tumor necrosis factor. Science (1985) 6.18
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med (1986) 4.99
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (1985) 4.98
Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature (1986) 4.06
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature (1985) 3.59
Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity. Proc Natl Acad Sci U S A (1985) 2.92
Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc Natl Acad Sci U S A (1985) 2.65
Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature (1986) 2.56
Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition. J Biol Chem (1985) 2.18
High affinity binding of 125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors. J Exp Med (1985) 2.00
Expression of the c-fms proto-oncogene during human monocytic differentiation. Nature (1985) 1.88
Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor. J Exp Med (1986) 1.77
Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol (1984) 1.64
Plating procedure for the enumeration of coliforms from dairy products. Appl Environ Microbiol (1978) 1.38
Cell cycle-specific effects of tumor necrosis factor. Cancer Res (1984) 1.28
Growth inhibition and cytotoxicity of tumor necrosis factor in L929 cells is enhanced by high cell density and inhibition of mRNA synthesis. J Immunol (1986) 0.97
Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein. Proc Natl Acad Sci U S A (1985) 0.96
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med (1999) 16.57
Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. J Natl Cancer Inst (2000) 4.20
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res (1999) 4.17
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature (1995) 2.54
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res (1983) 2.46
Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (1998) 2.29
Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J Clin Invest (1988) 2.29
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res (1997) 2.22
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem (1995) 2.11
Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res (2000) 2.06
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A (1989) 2.05
Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control (1998) 2.04
Individual classification of mild cognitive impairment subtypes by support vector machine analysis of white matter DTI. AJNR Am J Neuroradiol (2012) 2.04
Integrating family medicine and pharmacy to advance primary care therapeutics. Clin Pharmacol Ther (2008) 2.04
Medical service redesign shares the load saving 6000 bed days and improving morale. Intern Med J (2014) 2.00
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol (1986) 1.94
Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol (2000) 1.91
New York City syndromic surveillance systems. MMWR Morb Mortal Wkly Rep (2004) 1.91
Manipulation of the small intestine as a cause of the increased inflammatory response after open compared with laparoscopic surgery. Br J Surg (2006) 1.88
On the adsorption of proteins on solid surfaces, a common but very complicated phenomenon. J Biosci Bioeng (2001) 1.80
Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis (2009) 1.76
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst (1988) 1.73
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol (1994) 1.67
Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res (1980) 1.66
Involvement of FGF-8 in initiation, outgrowth and patterning of the vertebrate limb. Development (1996) 1.61
Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial. DIrect Stenting of COronary Arteries. Eur Heart J (2002) 1.61
Spatial and temporal control of gene therapy using ionizing radiation. Nat Med (1995) 1.59
A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 1.59
Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med (1989) 1.59
Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem (1980) 1.58
Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest (1988) 1.53
Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest (1996) 1.52
Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci U S A (1990) 1.50
Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther (1998) 1.50
Quantitative in vivo measurement of thyroidal iodine content by static x-ray fluorescent technique: some preliminary clinical observations. Invest Radiol (1979) 1.49
Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest (1985) 1.49
Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. J Immunol (1987) 1.49
Determinants of DNA yield and quality from buccal cell samples collected with mouthwash. Cancer Epidemiol Biomarkers Prev (2001) 1.49
Nasal continuous positive airway pressure in patients with COPD in acute respiratory failure. A study of the immediate effects. Chest (1993) 1.48
Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies. J Biochem (1972) 1.48
Photodynamic therapy in the canine prostate using motexafin lutetium. Clin Cancer Res (2001) 1.43
Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl (2006) 1.43
Toxoplasma gondii: redistribution of monoclonal antibodies on tachyzoites during host cell invasion. Exp Parasitol (1985) 1.43
Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry (2002) 1.43
Prognosis of patients treated with whole-brain radiation therapy for metastatic gestational trophoblastic disease. Gynecol Oncol (1998) 1.42
Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. Cancer Res (1989) 1.41
Utility of medical ethics. Intern Med J (2003) 1.38
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
Dorsal cell fate specified by chick Lmx1 during vertebrate limb development. Nature (1995) 1.37
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood (1997) 1.37
Proteome analysis of rat hepatic stellate cells. Hepatology (2000) 1.34
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res (1988) 1.34
Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem (1990) 1.32
Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci U S A (1993) 1.32
Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol (1998) 1.27
Expression of the macrophage-specific colony-stimulating factor in human monocytes treated with granulocyte-macrophage colony-stimulating factor. Blood (1987) 1.26
Stable behaviors associated with adults' 10-year change in body mass index and likelihood of gain at the waist. Am J Public Health (1997) 1.25
Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci U S A (1992) 1.25
Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest (2000) 1.25
Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood (1996) 1.24
Epidemiological research at the American Cancer Society. Cancer Epidemiol Biomarkers Prev (2000) 1.23
Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J Bone Miner Res (1991) 1.21
Major surface protein of Toxoplasma gondii (p30) contains an immunodominant region with repetitive epitopes. Eur J Immunol (1985) 1.20
Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci U S A (1981) 1.20
Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J Cell Physiol (1998) 1.20
The purine-cytosine permease gene of Saccharomyces cerevisiae: primary structure and deduced protein sequence of the FCY2 gene product. Mol Microbiol (1990) 1.19
Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene (1999) 1.19
Quantitative trait locus mapping for meat quality traits in an Iberian x Landrace F2 pig population. J Anim Sci (2002) 1.18
Nucleocytoplasmic shuttling of Smad1 conferred by its nuclear localization and nuclear export signals. J Biol Chem (2001) 1.18
Patterns of inpatient surgeries for the top four cancers in the United States, National Hospital Discharge Survey, 1988-95. Cancer Causes Control (2000) 1.16
Posttranscriptional stabilization of c-fms mRNA by a labile protein during human monocytic differentiation. Mol Cell Biol (1989) 1.16
Identification of a nucleolin binding site in human topoisomerase I. J Biol Chem (1996) 1.15
Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer (2000) 1.15
Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis. J Biol Chem (1997) 1.15
Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. Am J Epidemiol (2014) 1.14
Differential specificities of single mitral cells in rabbit olfactory bulb for a homologous series of fatty acid odor molecules. J Neurophysiol (1992) 1.14
Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res (1992) 1.14
Biological consequences of gene regulation after ionizing radiation exposure. J Natl Cancer Inst (1991) 1.13
Multivitamin use and colon cancer mortality in the Cancer Prevention Study II cohort (United States). Cancer Causes Control (2001) 1.13
Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res (1998) 1.13
Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci (2003) 1.12
Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res (1997) 1.12
DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer (1996) 1.11
Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol (1997) 1.10
TrialDB: A web-based Clinical Study Data Management System. AMIA Annu Symp Proc (2003) 1.10
Expression of the macrophage specific colony-stimulating factor (CSF-1) during human monocytic differentiation. Biochem Biophys Res Commun (1986) 1.10
Effect of tumor necrosis factor on GTP binding and GTPase activity in HL-60 and L929 cells. J Biol Chem (1988) 1.10
5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem (1981) 1.09
C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma (1998) 1.09
Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res (1994) 1.09
Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol (1997) 1.08